TD Cowen analyst Josh Jennings has maintained their neutral stance on ZBH stock, giving a Hold rating today.
Josh Jennings has given his Hold rating due to a combination of factors surrounding Zimmer Biomet Holdings’ strategic initiatives. The company has presented a comprehensive growth strategy that includes leveraging its innovative products like the Persona knees and Z1 hip stem to capture market share in the near term. However, the longer-term growth is dependent on the successful implementation of personalized interventions and regenerative therapies, which could present execution risks.
Furthermore, Zimmer Biomet’s focus on enhancing patient awareness, infection control, and procedural efficiency is promising, yet the transition to Ambulatory Surgery Centers and the integration of advanced digital solutions may take time to yield significant results. The company’s ambition to diversify beyond traditional orthopedics into broader healthcare areas is a strategic move, but it also introduces uncertainties as it ventures into new markets. These factors collectively suggest a cautious outlook, justifying the Hold rating as the company navigates these strategic shifts.
In another report released today, Morgan Stanley also maintained a Hold rating on the stock with a $115.00 price target.
Based on the recent corporate insider activity of 31 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ZBH in relation to earlier this year.
Questions or Comments about the article? Write to editor@tipranks.com